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Role of Human Corneal Stroma-
Derived Mesenchymal-Like Stem 
Cells in Corneal Immunity and 
Wound Healing
Zoltán Veréb1, Szilárd Póliska2, Réka Albert1, Ole Kristoffer Olstad3, Anita Boratkó4, 
Csilla Csortos4, Morten C. Moe5, Andrea Facskó1 & Goran Petrovski1,5
Corneal tissue regeneration is of crucial importance for maintaining normal vision. We aimed to isolate 
and cultivate human corneal stroma-derived mesenchymal stem-like cells (CSMSCs) from the central 
part of cadaver corneas and study their phenotype, multipotency, role in immunity and wound healing. 
The isolated cells grew as monolayers in vitro, expressed mesenchymal- and stemness-related surface 
markers (CD73, CD90, CD105, CD140b), and were negative for hematopoietic markers as determined 
by flow cytometry. CSMSCs were able to differentiate in vitro into fat, bone and cartilage. Their gene 
expression profile was closer to bone marrow-derived MSCs (BMMSCs) than to limbal epithelial stem 
cells (LESC) as determined by high-throughput screening. The immunosuppressive properties of 
CSMSCs were confirmed by a mixed lymphocyte reaction (MLR), while they could inhibit proliferation 
of activated immune cells. Treatment of CSMSCs by pro-inflammatory cytokines and toll-like receptor 
ligands significantly increased the secreted interleukin-6 (IL-6), interleukin-8 (IL-8) and C-X-C motif 
chemokine 10 (CXCL-10) levels, as well as the cell surface adhesion molecules. CSMSCs were capable 
of closing a wound in vitro under different stimuli. These cells thus contribute to corneal tissue 
homeostasis and play an immunomodulatory and regenerative role with possible implications in future 
cell therapies for treating sight-threatening corneal diseases.
The cornea is the transparent front part of the eye responsible for two-thirds of its refractive power. It serves as a 
first barrier against external pathogens. Up to 90% of the corneal thickness is composed of corneal stroma, which 
contains different types of cells packed between regularly stacked and equally spaced collagen fibrils. Viral, fungal, 
bacterial infections and injuries caused by physical or chemical agents can all cause corneal scar formation, which 
eventually leads to vision loss or blindness1–3. The damage of the corneal epithelial cell layer and the deeper stro-
mal layer invoke a healing process mediated by activation of progenitor cells that are found in the limbal region 
of the cornea- the limbal epithelial stem cells (LESCs)3–6. These cells can be found in six limbal crypts ordered in 
special niches capable of differentiating into transient amplifying cells (TACs) and differentiated corneal epithelial 
cells (CECs)7–10. The regeneration of the cornea and the role of CECs play is not fully understood. It is hypothe-
sized that TACs migrate centripetally and superficially during differentiation or, alternatively, the LESCs migrate 
to the site of injury9. LESCs can express mesenchymal stem cell (MSC)-like markers on their surface such as 
CD73, CD90 and CD105 and show potential for clonal expansion, however, these cells are distinct from MSCs11. 
LESC deficiency can lead to abnormal epithelial regeneration and visual loss1,12, but such deficiency in mice could 
not stop the corneal epithelial regeneration in the central part of the cornea, suggesting another type of progen-
itor/stem-like cells plays a role in the wound healing process13,14. Corneal stroma stem cells have been isolated 
from the limbal stroma of mice and differentiated into keratocytes, but no evidence exists whether these cells are 
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MSC- or bone marrow-derived MSC(BMMSC)-like13. In humans, both CD34+ and CD34- as well as CD105+ 
cells have been isolated from the corneal stroma, however, no data demonstrates the stemness and multipotency 
of these cells, nor has their specific immunosuppressive effect been shown15,16. Furthermore, nothing is known 
about the participation of corneal stroma stem cells in corneal tissue remodelling and immunomodulatory pro-
cesses related to trauma or infections17.
In this study, we isolated and characterized human central corneal stroma stem cells and compared their 
genotype to LESCs and BMMSCs, as well as their surface marker phenotype to BMMSCs. In addition, their differ-
entiation potential and the immunological and wound healing properties were tested ex vivo to possibly harvest 
such cells for future cell, immunosuppressive and wound healing therapy in humans6.
Materials and Methods
Cell cultures. Collection of corneal and limbal tissue and bone marrow samples complied with the guide-
lines of the Helsinki Declaration and was approved by the Regional Ethical Committee (DEOEC RKEB/IKEB 
3094/2010 and 14387/2013/EKU-182/2013), which follows the EU Member States’ Directive 2004/23/EC on pre-
sumed consent practice for tissue collection18. Corneal buttons were removed from cadavers (Age: 72.3 ± 11.4 
years, Sex: 13F/11M) within 24 hrs from death, then transferred into Dulbecco’s Modified Eagle Medium-
(DMEM) (PAA Laboratories GmbH, Pasching, Austria) containing wells. Thorough rinsing with Betadine 
(Povidone-iodine solution, Purdue Pharma L.P. Stamford, Connecticut, USA) and PBS took place, after which 
the epithelium and the Bowman’s membrane were scraped off using a surgical knife; consequently, the cor-
neal endothelium and the Descemet’s membrane were scraped off with the same method. Just the central part 
(approximately 6–7 mm diameter cube) of the cornea was used and cut into small square pieces. Grafts were 
plated to 24-well cell culture plates and cultivated in 1 mL DMEM-LG medium (DMEM Low glucose-containing 
medium, PAA Laboratories) supplemented with 10% fetal calf serum (FCS) (Gibco; Gibco, London, UK), and 
1% Antibiotic-antimycotic solution (PAA Laboratories). Medium was changed every alternate day. Limbal tissue 
processing and isolation of LESCs has been described by our group previously19. For the isolation of BMMSCs, 
approximately 10 mL of bone marrow aspirate was obtained from the donors and then diluted by saline in a 1 to 
3 ratio. The mononuclear cells were recovered by Ficoll Histopaque (Amersham Biosciences, Uppsala, Sweden) 
density gradient centrifugation. The number of live cells was determined by Trypan blue exclusion assay. Bone 
marrow nucleated cells (BMNC) were plated in 25 cm2 flasks at a density of 2 × 105 living cells/cm2 and cultured 
in DMEM-LG medium, supplemented with 10% FCS and 1% Antibiotic-Antimycotic Solution (all obtained from 
PAA Laboratories). At passage 5, every cell culture was tested for antigen expression by flow cytometry, in vitro 
differentiation assays and absence of Mycoplasma (Lonza, Basel, Switzerland).
Flow cytometry and immunochemistry. To analyze the expression of selected surface markers, 
three-color flow cytometry was used. The cells were stained on ice for 30 min with fluorochrome-conjugated anti-
bodies, then measured on a FACS Calibur flow cytometer (BD Biosciences Immunocytometry Systems, Franklin 
Lakes, NJ). The data were analyzed using Flowing Software (Cell Imaging Core, Turku Centre for Biotechnology, 
Finland) and the results were expressed as means of positive cells (%) ± SD. For immunohistochemistry 
studies, cell cultures were fixed in 4% PFA. Cytoskeletal actin filaments were labelled by phalloidin-TRITC 
(Sigma-Aldrich, Budapest, Hungary) and the nuclei by Hoechst 33342 (Invitrogen, Oregon, USA). Samples were 
examined under an Olympus IX81 inverted microscope with MT20 station (Olympus, Münster, Germany) and 
Orca2 (Hamamatsu Photonics K.K., Japan) camera. Surface carbohydrate molecules were labelled with lectins 
(Vector Labs, Burlingame, CA) diluted in Hepes buffer (Sigma-Aldrich)and examined by Olympus FluoView 
1000 confocal LSM (Olympus).
Differentiation. To undertake trilineage differentiation, the isolated cells were applied to commercially 
available Gibco’s StemPro® Adipogenesis, Osteogenesis and Chondrogenesis Differentiation Kits (Gibco). All 
differentiation patterns were evaluated according to the manufacturer’s guidelines. Oil red O staining was used to 
detect the lipid-laden particles in the differentiated adipocytes. The mineral deposits during osteogenesis could 
be demonstrated by Alisarin red staining, while toluidine blue staining was used to label the chondrogenic mass 
formed by CSMSCs.
Microarray data analysis. To compare the gene expression profiles of the different cells isolated, an 
Affymetrix Gene Chip Human Gene 1.0 ST Array (Affymetrix, Santa Clara, CA, USA) was used. 150 ng of total 
ribonucleic acid (RNA) was subjected to an Ambion WT Expression Kit (Thermo Fisher Scientific, Waltham, 
MA, USA) and a GeneChip WT Terminal Labeling Kit (Affymetrix) according to the manufacturers’ protocol, 
then washed and stained on FS-450 fluidics station (Affymetrix). The signal intensities were detected by Hewlett 
Packard Gene Array Scanner 3000 7 G (Hewlett Packard, Palo Alto, CA, USA). The scanned images were pro-
cessed using GeneChip Command Console Software (AGCC) (Affymetrix) and the CEL files were imported into 
GeneSpring GX 12.6 software (Agilent Technologies Inc, Santa Clara, CA, USA). Robust microarray analysis 
(RMA) was applied for normalization. Based on the literature, stem cells-related genes were selected and statis-
tical analysis was performed (One-way ANOVA with Tukey post hoc test and Benjamini-Hochberg FDR; fold 
change cut off being set at 2) to calculate p values and fold change.
Activation of CSMSCs and quantification of cytokines released by ELISA. CSMSCs were seeded 
onto 24 well plates in 5 × 104 cell/mL density. After 24 h of culturing, the cells were treated with ultrapure 1 μ g/mL 
lipopolysaccharide (LPS) (InvivoGen, San Diego, CA, USA), 25 μ g/ml Polyinosinic-polycytidylic acid (Poly:IC) 
(InvivoGen), 100 ng/mL tumor necrosis factor alpha (TNFα ), 10 ng/mL interferon gamma (IFNγ ) and 10 ng/mL 
interleukin 1 beta (IL-1β ) (all from Preprotech, Rocky Hill, NJ, USA) in a fresh medium for additional 12 and 
24 h. After the incubation, supernatants were harvested and kept at − 20 °C till measurement. The concentration 
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of the secreted cytokines was measured by an enzyme-linked immunosorbent assay (ELISA). BD OptEIA ELISA 
assay kits for IL-1β , interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), interleukin-12 (IL-12), 
IFNγ , TNFα and IFNγ -inducible protein 10/C-X-C motif chemokine 10 (IP10/CXCL10) were used following 
the supplier’s instructions (BD Pharmingen, San Diego, CA, USA).
Western blot analysis. For this purpose, cells were cultured into 25 cm2 cell culture flasks. After activation 
with the appropriate cytokines and toll-like receptor (TLR) ligands (described earlier), the whole cell lysates 
were prepared by scraping cells in 1000 μ L of ice-cold radioimmunoprecipitation assay (RIPA) buffer containing 
protease and phosphatase inhibitors (all from Thermo Fisher Scientific)according to the manufacturer’s recom-
mendations. The lysates were centrifuged at 4 °C at 12000 g for 10 min to clear the cellular debris. Total protein 
was quantified using the Bradford protein assay kit (Sigma-Aldrich). Equal amounts of protein were separated 
by 10% SDS-PAGE electrophoresis and transferred to a nitrocellulose membrane using a semi-dry blotting sys-
tem (Biorad, Hercules, CA USA) and labelled with the following antibodies: anti–glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) (1:5000; Covalab, Villeurbanne, France), nuclear factor of kappa light polypeptide 
gene enhancer in B-cells inhibitor (Iκ B) (1:1000; Cell Signaling, Danvers, MAUSA), p65 and p50 (nuclear fac-
tor kappa-light-chain-enhancer of activated B cells/NFκ B;1:1000; Cayman Chemicals, Ann Arbor, Michigan, 
USA); matching horseradish-peroxidase (HRP)-conjugated species corresponding secondary antibody (1:10000; 
Sigma-Aldrich) was also used. Enhanced chemiluminescence system (Immobilion substrate, Millipore, Merck 
KGaA, Darmstadt, Germany) was applied to visualize the immunoreaction, which was then developed by Kodak 
X-ray film system (Kodak, Rochester, NY, USA).
Mixed lymphocyte reaction and mitogen-induced cell proliferation. Peripheral blood mononu-
clear cells (PBMCs) were isolated by a Ficoll gradient centrifugation (Amersham Biosciences). Mitogen-activated 
T lymphocyte proliferation was induced by concanavalin A (ConA) or phytohemagglutinin (PHA, all from 
Sigma-Aldrich) used at a final concentration of 10 μ g/mL and 1 μ g/mL, respectively, added to 1 × 106 PBMCs. 
CSMSCs were added to 1 × 106 PBMCs at 104, 2 × 104 and 105 cell numbers and co-cultured for 3 days. On day 
three, proliferation was detected by a BrDU colorimetric assay directly in the cell culture plate according to the 
manufacturer’s instructions (Roche, Budapest, Hungary).
ECIS based wound healing assay. For studying wound healing in vitro, a standardized commer-
cially available wound healing assay was used implemented via automated ECIS Zθ (Theta)system (Electric 
cell-substrate impedance sensing system, purchased from Applied BioPhysics Inc, Troy, NY, USA). Cells were cul-
tured at 2 × 104 density in the chamber of the ECIS electrode arrays (8W10E obtained from Applied BioPhysics). 
After cell inoculation, the wells were incubated overnight to form monolayers; wounding was performed by elec-
troporation using voltage pulses with 40 kHz frequency, 3.5 V amplitude and 30 s duration. This led to the death 
and detachment of cells present on the small active electrode, which resulted in a standardized wound size which 
normally healed from the cells surrounding the small active electrode not being subjected to an elevated voltage 
pulse. Continuous impedance measurements started 2 h before wounding occurred and continued until 24 h. The 
following experimental setups were performed: i) cells treated with TLR ligands and pro-inflammatory cytokines 
and impedance measured without making a wound; ii) cells treated with TLR ligands and pro-inflammatory 
cytokines after making a wound; iii) cells treated with TLR ligands and pro-inflammatory cytokines before 
Lectin Positive Cells (%) Sugar Specificity
ConA 80.38 ± 5.36 α -mannose, α - D-glucose
GSL I 0.00 ± 0.00 α - D-galactose, α linked N-acetylgalactosamine
AIL 90.86 ± 1.85 (Sialic Acid)β 1 D-galactose -3 α 1 N-acetylgalactosamine
WGA 92.19 ± 2.34 α - or β -linked N-acetylglucosamine
UEA 0.00 ± 0.00 α 1 L-fucose-2 D-galactose
SBA 8.15 + 5.66 β 1 N-acetylglucosamine – 4 β 1 N-acetylglucosamine, 4 N-acetylglucosamine - N-acetylneuraminic acid (sialic acid)
RCA 84.35 ± 6.11 α - or β -linked N-acetylgalactosamine
PNA 6.31 ± 5.68 β 1 D-galactose − 3 α 1 N-acetylgalactosamine
DBA 1.10 ± 0.72 N-acetylgalactosamine
succinylated WGA 80.93 ± 8.21 N-acetylglucosamine
PSA 81.94 ± 6.26 α -mannose, α - D-glucose
PHA-L 78.00 ± 7.23 β 4 D-galactose-4 β 6 N-acetylglucosamine (β 2N-acetylglucosamine - α 3 mannose) α 3 mannose
PHA-E 86.50 ± 3.76 β 4 D-galactose - β 2N-acetylglucosamine - α 6 mannose (β 4 N-acetylgalactosamine) β 4 N-acetylgalactosamine - α 3 mannose) – β 4 mannose
LCA 84.00 ± 5.51 α -mannose, α - D-glucose
Table 1.  Expression of carbohydrate molecules on the surface of in vitro cultured CSMSCs. Majority of the 
CSMSCs contained mannose, glucose, poly-saccharides with N-acetylglucosamine and N-acetylgalactosamine 
molecules, and lacked fucose, based upon the specific lectin screening. These carbohydrate molecules could 
determine the extracellular matrix and/or cell-cell binding and immunological properties of the cells (Data 
shown are mean ± SEM, N = 8; for abbreviations see Fig. 1).
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Figure 1. Morphology of the in vitro CSMSC cultures. Corneal stroma graft (*) isolated from the central 
part of the cornea was cultured in a cell culture plate (A), giving rise to elongated cells in the first 14 days 
of in vitro culture. Cells formed a monolayer by day 28, and showed fibroblastoid morphology according to 
their cytoskeletal structure. The expression of carbohydrate molecules on the surface of CSMSCs labelled 
by fluorescein-conjugated lectins is being shown (B). GSL I: Griffonia (Bandeiraea) simplicifolialectin 
I (Griffoniasimplicifolia); LCA: Lens culinaris agglutinin (Lens culinaris); PHA E: Phaseolus vulgaris 
erythroagglutinin (Phaseolus vulgaris); PHA L: Phaseolus vulgaris leucoagglutinin (Phaseolus vulgaris); PSA: 
Pisumsativum agglutinin (Pisumsativum; sWGA: succinylatedWheat germ agglutinin (Triticum vulgaris); DBA: 
Horse gram lectin/Dolichosbiflorus agglutinin (Dolichosbiflorus); ConA: Concanavalin A (Canavaliaensiformis); 
PNA: Peanut agglutinin (Arachishypogaea); RCA 120: Ricinus communis agglutinin (Ricinuscommunis); SBA: 
Soy bean agglutinin (Glycine max); UEA: Ulexeuropaeus agglutinin (Ulexeuropaeus); WGA: Wheat germ 
agglutinin (Triticum vulgaris); AIL: Jacalin(Artocarpusintegrifolia) (Magnification: 100X A1-3; 200XB1-14, 
Phalloidin-TRITC staining A-3, 400× Lectin staining B1-14).
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making a wound; iv) non-treated controls. All experiments were performed at least three times and in triplicates 
on three independent donors.
Statistical analysis. Statistica 7.0 software (StatSoft Inc., USA) was used for the statistical analyses. 
Normality of distribution of data was tested by Kolmogorov-Smirnov and Lilliefors test. Non-normally distrib-
uted parameters were transformed logarithmically to correct their skewed distributions. R software was used for 
hierarchical clustering. Each experiment was performed at least three times and each sample was tested in tripli-
cates. Data are expressed as mean ± SD or SEM. Statistically significant difference was determined with two way 
ANOVA analysis when there were more than two groups, while analysis between two groups was performed with 
a paired student-t test. A value of p < 0.05 was considered significant.
Results
Cell morphology and surface carbohydrate characterization. Attached cells were detected after 
10–14 days from human corneal stroma isolation in the culture plates as outgrowth from the graft, and formed 
a monolayer by 4 weeks (Fig. 1A). The outgrowing cells exhibited fibroblastoid morphology, assuming an elon-
gated or spindle shape with a single nucleus. The established cell cultures could be maintained for more than 
10 passages. At passage 5, cells were positive for RCA lectin which recognizes terminal galactose molecules 
(Fig. 1B). The two forms of Wheat germ agglutinins showed the succinylated and non- succinylated forms of 
dimer and trimer N-acetylgalactosamines on the isolated cells. High amount of mannose and D-glucose mon-
omers and polymers could be detected by LCA, PSA, ConA and PHA-E (with N-acetylglucosamine) lectins, 
respectively. AIL labelled the β -galactose (1,3) N-acetylgalactosamine, which is the O-glycosidically linked oli-
gosaccharide part of the T-antigen, while PNA negativity proved missing total T-antigen. The monomer form of 
N-acetylgalactosamine was not detected on the surface of the isolated and cultivated cells as DBA, SBA, GSL-I 
staining was similar to the unlabeled control. The well-known endothelial and epithelial marker UEA I (recog-
nizing L-fucose) was also missing on these cells (Fig. 1B). RCA 120, ConA, WGA and AIL positivity could be 
detected more in the web-like structures between the cells, unlike LCA, sWGA and PHA-E which showed cellular 
localization. These findings could be verified by FACS measurements as well (Table 1).
Gene expression analysis. Genes related to stemness (386), differentiation and lineage (468), cell cycle 
(220) and HOX, suppressor of cytokine signaling (SOCS), Notch signalling (372) were collected into functional 
groups and analyzed. The hierarchical clustering in CSMSCs clearly separated them from LESCs and BMMSCs, 
but formed a higher cluster with the BMMSCs (Fig. 2). In detail, an expression pattern of 12 genes related to 
stemness was found to be specific for CSMSCs, whereas SLC48A1 (solute carrier family 48 member 1) and DLL1 
(delta-like1-Drosophila) expression was lower than in BMMSCs or LESCs. A significantly higher expression of 
C12orf75 (chromosome 12 openreadingframe 75), EDNRB (endothelinreceptortypeB), SMURF2 (SMAD-specific 
E3 ubiquitin proteinligase 2), ACVR1 (activating A receptor type I), TGFBR2 (transforming growth factor 
beta receptor II), GATA2 (GATA binding protein 2), putative stem cell marker ABCG2 (ATP-binding cassette 
sub-family G member 2), LIFR (leukemia inhibitory factor receptor alpha), HSPA9 (heatshock 70 kDa protein 9/
mortalin) and CCND3 (cyclin D3) was determined as well. In the HOX, SOCS, Notch signalling superfamily, the 
CSMSC-specific pattern contained the following genes with low expression: HES5 (hairy and enhancer of split 
5-Drosophila), WNT4 (wingless-type MMTV integration site family member 4), WNT9A (wingless-type MMTV 
integration site family member 9 A), CCND2 (cyclin D2), CREBBP (CREB-binding protein), KREMEN1 (krin-
gle containing transmembrane protein 1), CTNNB1 (catenin cadherin-associated protein beta 1), FST (follista-
tin), EGR1 (early growth response 1), MSX2 (msh homeobox 2), PITX1 (paired-like homeodomain 1), RUNX2 
(runt-related transcription factor 2), EGR3 (early growth response 3), and the following genes with high expres-
sion: NFKB2 (nuclear factor of kappa light polypeptide gene enhancer in B-cells 2), FOSL1 (FOS-like antigen 
1), LRP6 (low density lipoprotein receptor-related protein 6), SEL1L (sel-1 suppressor of lin-12-like-C.elegans), 
TCF4 (transcription factor 4), CALM2/CALM3/CALM1 (calmodulin 2/calmodulin 3/calmodulin 1 phosphoryl-
ase kinase delta), IRS1 (insulin receptor substrate 1), RBPJ (recombination signal-binding protein for immuno-
globulin kappa J region), GJA1 (gap junction protein alpha1) and MYC (v-myc myelocytomatosis viral oncogene 
homologue), respectively.
The gene profile of CSMSCs in the differentiation and lineage custom group were: MDK (midkineneurite 
growth-promoting factor 2), IGF1R (insulin-like growth factor 1 receptor), NTN1 (netrin 1), RUNX1 (related 
transcription factor 1) and DLL1 had lower expression compared to BMMSCs or LESCs; higher expression was 
detected in: ACVR1 (activin A receptor type I), TGFBR2 (transforming growth factor beta receptor II), GATA2 
(GATA binding protein 2) and GDNF (glial cell-derived neurotrophic factor).
Genes related to proliferation and cell cycle were distinct for CSMSCs and contained high levels of NHP2 and 
CCND3 (cyclin D3), low levels of JUNB (junB proto-oncogene), BCL2L1 (BCL2-like1), RUNX1, FHIT (fragile 
histidine triad) and CDKN2B (cyclin-dependent kinase inhibitor 2B).
Phenotype of CSMSCs. Despite existence of the International Society for Cell Therapy (ISCT) defined most 
important markers of human MSCs, a clear MSC phenotype has not yet been well described. Our cells expressed 
the most important markers of MSCs such as CD73 (96.43 ± 3.88%, mean ± SD), CD90 (89.87 ± 8.80%), CD105 
(76.99 ± 31.05%) and CD140b/PDGFRβ (76.63 ± 25.00%), but were negative for CD34, CD45, CD133, HLA-DR, 
which are markers of hematopoietic lineage or activated cells. Moreover, expression of other hematopoietic, fibro-
blast, endothelial-related markers, as well as integrins and cell adhesion molecules (CAMs) on the surface of 
CSMSCs were being determined (Table 2). No endothelial cells were detected within the CSMSC cultures, as 
VEGFR2, CD31 and CD104 were non-detectable. Furthermore, hematopoietic cell markers were absent (CD11, 
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CD69) or the expression was low in the case of CD14 (1.39 ± 3.58%) and CD36 (5.80 ± 4.57%), respectively 
(the later results having a high interdonor variability being observed). Majority of the cells expressed CD49a/
Figure 2. Heatmap of the differentially expressed genes in CSMSCs compared to LESCs and BMMSCs. 
Different expression levels of the transcripts and functional clustering of the genes expressed in in vitro cultured 
CSMSCs, LESCs and BMMSCs. Genes related to stemness, HOX, Notch and SOX signalling, differentiation 
and lineage, cell cycle and oncogenes were selected. The cluster analysis and dendrograms show the difference 
between the three cell types, and strengthen the finding that CSMSCs are more closely related to BMMSCs than 
to LESCs. Red and yellow colors indicate high and low expression, respectively.
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Integrin α 1 (95.55 ± 7.15%), CD49b/Integrin α 2 (98.05 ± 1.45%) and CD29/Integrin β 1 (95.25 ± 6.95%). More 
than half of the cell cultures showed CD49d/Integrin α 4 (61.75 ± 21.16%) positivity, few cells being positive for 
CD49f/Integrin α 6 (3.03 ± 4.10%) and CD51/Integrin α V (16.62 ± 15.81%) besides their lack of CD104/Integrin 
β 4 and CD18/Integrin β 2 molecules. CAM molecules were highly expressed in the CSMSCs: CD44/H-CAM 
(96.07 ± 5.53%), CD166/ALCAM (93.44 ± 10.21%) and CD144/VE-Cadherin (94.56 ± 3.80%). A small subpop-
ulation of the cells showed presence of CD325/N-Cadherin (27.72 ± 37.51%), CD146/MCAM (24.65 ± 24.97%), 
CD147/Neurothelin (69.49 ± 47.52%), CD54/ICAM-1 (24.79 ± 25.46%) and CD56/NCAM (17.21 ± 18.76%) 
positivity, however, huge interdonor variance was observed, respectively. Only a few cells were found to be CD106/
VCAM-1 (2.11 ± 6.12%), CD112/Nectin (3.90 ± 8.85%) positive in some donors. CD117/c-kit (21.29 ± 34.25%) 
and CD338/ABCG2 (3.45 ± 5.03%) describe stem cell subsets and were found in some cases within the CSMSC 
cultures, but no cells could show measurable C-X-C chemokine receptor type 4 (CXCR4) expression. The 
high CD47 positivity (96.15 ± 7.02%) proved the viability and the immune competence of CSMSCs (Table 2). 
Comparative cluster analysis of the different surface markers showed that CSMSCs share similar phenotype to 
BMMSCs, and both cell types are different from the LESCs phenotype in vitro (Fig. 3A).
Differentiation and immunomodulatory potential of CSMSCs. One of the hallmarks of human 
MSCs is their ability to differentiate into adipocytes, chondrocytes and osteocytes in culture. We assessed the 
in vitro differentiation potential of CSMSCs by culturing them into osteogenic, adipogenic, and chondrogenic 
Marker Positive Cells (%)
CD11a (LFA-1) 0.00 ± 0.00
CD14 1.39 ± 3.58
CD18 (Integrin β 2) 0.00 ± 0.00
CD29 (Integrin β 1) 95.25 ± 6.95
CD31 (PECAM) 0.00 ± 0.00
CD34 0.00 ± 0.00
CD36 5.80 ± 4.57
CD44 (H-CAM, Hermes) 96.07 ± 5.53
CD45 0.00 ± 0.00
CD47 96.15 ± 7.02
CD49a (Integrin α 1) 95.55 ± 7.15
CD49b (Integrin α 2) 98.05 ± 1.45
CD49d (Integrin α 4) 61.75 ± 21.16
CD49f (Integrin α 6) 3.03 ± 4.10
CD51 (Integrin α V) 16.62 ± 15.81
CD54 (ICAM-1) 24.79 ± 25.46
CD56 (NCAM) 17.21 ± 18.76
CD69 0.00 ± 0.00
CD73 96.43 ± 3.88
CD90 (Thy-1) 89.87 ± 8.80
CD104 (Integrin β 4) 0.00 ± 0.00
CD105 76.99 ± 31.05
CD106 (VCAM-1) 2.11 ± 6.12
CD112 (Nectin) 3.90 + 8.85
CD117 (c-kit) 21.29 ± 34.25
CD133 0.00 ± 0.00
CD140b (PDGFRβ ) 76.63 ± 25.00
CD144 (VE-Cadherin) 94.56 ± 3.80
CD146 (MCAM) 24.65 ± 24.97
CD147 (Neurothelin) 69.49 ± 47.52
CD166 (ALCAM) 93.44 ± 10.21
CD184 (CXCR4) 0.00 ± 0.00
CD325 (N-Cadherin) 27.72 ± 37.51
CD338 (ABCG2) 3.45 ± 5.03
HLA-DR 0.00 ± 0.00
VEGFR2 0.00 ± 0.00
Table 2.  Surface marker pattern of in vitro cultured CSMSCs. Surface markers’ profiling of the in vitro 
cultured CSCMSCs is being shown. High expression of well-known MSC markers such as CD73, CD90, CD105 
and CD140b/PDGFRβ was detected. Importantly, CSMSCs showed no measurable expression of hematopoietic 
and endothelial markers (Data shown are mean ± SD, N = 14).
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Figure 3. MSC-related phenotype, differentiation potential and immunosuppressive effects of in vitro 
cultured CSMSCs. Hierarchical clustering of cell surface molecules’ expression divided the stem cells of 
different tissue origin into two upper classes: CSMSCs were more closely related to BMMSC than to LESCs  
(A) (Color key represents percentage of positive cells in the in vitro cell cultures). CSMSCs were able to 
differentiate into the canonical mesodermal lines in vitro. Osteogenic differentiation shows the calcium 
deposits present as red-brown hue in the cell cultures visualized by Alizarin-red staining. Oil Red-O stained 
lipid droplet accumulations are shown in the adipocytes derived from CSMSCs in vitro. Metachromasia of 
the extracellular matrix stained by toluidine blue is shown in the cartilaginous section after chondrogenic 
differentiation (B). CSMSC could inhibit the proliferation of immune cells activated by PHA and ConA even 
in low cell numbers (left-hand panel) in vitro. Opposite to the mitogen-induced reaction, CSMSCs could block 
lymphocyte proliferation only at high doses in the mixed lymphocyte reaction (right-hand panel) (Data shown 
are mean ± SD, N = 3) (C).
www.nature.com/scientificreports/
9Scientific RepoRts | 6:26227 | DOI: 10.1038/srep26227
media. During the chondrogenic differentiation, the cells formed a micromass pellet after 24 h. Following three 
weeks of differentiation, sections were made from the chondrogenic mass culture and showed metachromasia 
upon toluidine blue staining due to presence of proteoglycans (Fig. 3B). Fat globules could also be seen after 
three weeks of adipogenic induction stained with Oil Red ‘O’ (Fig. 3B). When induced with osteogenic induction 
medium for two to three weeks, the cultures showed mineral deposition indicating early stages of bone formation 
(Fig. 3B).
The immunosuppressive properties of MSCs have been extensively studied in the past years due to a major 
potential for clinical applications. In the present study, mitogenic MLR was used to test the immunosuppressive 
Figure 4. Cytokine secretion by activated CSMSCs. The bar graphs illustrate results of the quantitation of 
cellular responses of cytokine production by in vitro cultured CSMSCs and BMMSCs of both IL-6 and IL-8 and 
in response to activation by TRL ligands (LPS, Poly:IC), as well as pro-inflammatory cytokines (TNFα , IFNγ, 
IL-1β ) observed after 12 h and 24 h intervals (A). Involvement of NFκ B and Iκ B in the signalling pathways 
initiated by the TLR ligands and pro-inflammatory cytokines is being shown (B). (Data shown are mean ± SEM; 
*p < 0.05 **p < 0.01 ***p < 0.001 N = 6 for the BMMSCs and N = 9 for the CSMSCs, respectively).
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properties of CSMSCs. PBMCs from healthy donors were used as responder cells, and ConA or PHA as mito-
genic activators. As shown in Fig. 3, the addition of CSMSCs to PBMCs and stimulation with ConA or PHA, 
suppressed the mitogenic response in a dose-dependent manner (Fig. 3C). In the MLR, no mitogenic activators 
were being used and only a high dose of CSMSCs was found to be immunosuppressive, whereas in low-doses, no 
anti-inflammatory function could be detected (Fig. 3C).
Cytokine release from CSMSCs upon pro-inflammatory activation. The secreted cytokines’ 
response of in vitro cultured CSMSCs and BMMSCs was investigated upon TLR ligands (LPS and Poly:IC) 
or pro-inflammatory cytokines’ activation at different time points (Fig. 4A). IL-6 showed constant and con-
tinuous baseline secretion by both MSC types under control or untreated conditions, and increased sig-
nificantly upon LPS treatment in CSMSCs (from 1098.98 ± 385.39 pg/mL to 13200.46 ± 2656.55 pg/mL 
at 12 h, and from 645.09 ± 327.64 pg/mL to 12883.07 ± 2335.30 pg/mL at 24 h time, respectively; data 
shown are mean ± SEM). Activation by Poly:IC, TNFα and IL-1β caused similar significant increase 
in the aforementioned baseline secretion of IL-6 by CSMSCs: 4295.81 ± 780.89 pg/mL (Poly:IC) and 
14265.89 ± 3381.12 pg/mL (IL-1β ) after 12 h, and 4843.41 ± 1049.07 pg/mL (Poly:IC), 4835.67 + 1836.90 pg/mL 
(TNFα ) and 16974.47 + 2912.13 pg/mL (IL-1β ) after 24 h, respectively. In case of IL-6 secretion, BMMSCs 
responded to all the treatments in the same manner as CSMSCs (Fig. 4A). Similar to the IL-6 response, 
however, the CXCL8/IL-8 and pro-inflammatory cytokines’ secretion was enhanced in CSMSCs 
upon TLR ligands treatment (Fig. 4A). Activation by LPS, TNFα and IL-1β caused even more robust 
and significant increase in the IL-8 release from the baseline secretion of 15472.92 ± 4532.47 pg/mL 
by the CSMSCs to 23710.37 ±   4195.08 pg/mL (LPS),  26084.64 ±   3765.65 pg/mL (TNFα ) 
and 23349.24 ± 4656.87 pg/mL (IL-1β ) after 12 h, and from the baseline secretion of 18253.36 + 4869.13 pg/mL to 
25174.19 + 4255.29 pg/mL (LPS), 26756.89 ± 4104.02 pg/mL (TNFα ) and 21066.17 ± 5529.87 pg/mL (IL-1β ) after 
24 h, respectively. Interestingly, IFNγ treatment caused a decreased release of IL-8 by the CSMSCs compared to 
the untreated control: from 7997.389 ± 4611.869 pg/mL after 12 h to 10631.81 ± 5042.48 pg/mL after 24 h, respec-
tively, while such treatment did not show suppressed secretion by the BMMSCs. Poly:IC treatment did not alter 
the secretion of IL-8 by the activated CSMSCs, and the inverse effect was observed in BMMSCs (Fig. 4A).
Untreated CSMSCs secreted low levels of CXCL10 (35.26 ± 29.65 pg/mL at 12 h and 52.05 ± 48.28 pg/mL 
at 24 h, respectively), which could not be observed in the BMMSCs. This basic secretion level increased upon 
LPS, Poly:IC and IFNγ treatments (669.98 ± 189.45 pg/mL, 781.27 ± 134.70 pg/mL and 589.31 ± 75.90 pg/mL 
after 12 h, and 771.32 ± 184.87 pg/mL, 894.98 ± 105.82 pg/mL and 642.10 ± 81.36 pg/mL after 24 h, respectively) 
(Fig. 4A). No IL-1β , IL-10, IL-12, IL-17, TNFα and IFNγ production could be detected in the supernatants after 
the same treatments (therefore, not shown). The activation of CSMSCs was NFκ B initiated: 10 mins after activa-
tion, only TNFα decreased the protein level of Iκ b, which phenomenon could be detected in the 20 and 30 min 
samples. Treatments with LPS and IL-1β also resulted in diminished Iκ b levels after 20 and 30 min of activa-
tion compared to untreated controls. The Poly:IC-dependent IL-6 and IL-8 secretion did not involve the Iκ B 
mediated pathway (Fig. 4B). Treatment of CSMSCs with inflammatory cytokines changed the level of cell adhe-
sion molecules as well. The percentage of positive cells forCD54/ICAM-1 was significantly increased upon LPS 
(53.1 ± 23.22%, mean ± SD), Poly:IC (56.85 ± 31.63%), TNFα (49.8 ± 23.75%), IFNγ (29.43 ± 11.23%) and IL-1β 
(34.9 ± 14.93%) treatment (Fig. 5) when compared to untreated controls. In case of CD106, increased expression 
was observed, however, the high interdonor variability accounted for its non-significant increase by the Poly:IC 
and IFNγ treatments. No activation of HLA-DR or CD11a was observed and CD47 remained constant under all 
treatment modalities, although, its expression decreased upon pro-inflammatory stimuli (Fig. 5A–C).
Wound healing properties of CSMSCs. The CSMSCs were able to close wounds showing robust regenera-
tion activity under standard conditions. This phenomenon changed when cells were treated by pro-inflammatory 
cytokines or TLR ligands and following wound formation in vitro. The time of closing wounds was prolonged 
or, in some cases, inhibited the closure of the wound as was the case with LPS (20.89 ± 2.97 h, p = 0.000001, 
mean ± SD), Poly:IC (17.81 ± 4.07 h, p = 0.00282); TNFα (18.51 ± 3.95 h, p = 0.00108), IL-1β (20.19 ± 4.36 h, 
p = 0.00287) and IFNγ (18.27 ± 3.95 h, p = 0.00156) compared to non-treated cells with a wound (control, 
12.37 ± 6.15 h) (Fig. 5D).
Discussion
An isolation and cultivation protocol is hereby presented for harvesting and expanding MSC-like cells from the 
central part of the human corneal stroma with the use of FCS. The in vitro cultured cells fulfilled the ISCT criteria 
for MSCs20, as they were adherent to the cell culture plastic, could differentiate into three different lineages and 
expressed the desired MSC markers (CD73, CD90, CD105 and CD140b/PDGFRβ ). The surface carbohydrate 
pattern of the corneal stroma stem-like cells, to date, has not been reported elsewhere. Previously, we published 
the carbohydrate fingerprint of in vitro cultured LESCs19, and in comparison to those cells, the in vitro cultured 
CSMSCs’ fingerprint differed significantly. The percentage of positive cells for the mannose and D-glucose bind-
ing ConA was higher in CSMSC cultures, with the concomitant decrease in UEA, PNA, DBA and SBA positivity. 
This different molecular pattern could reflect the different extracellular matrix niche of the two cell types. At gene 
expression level, the in vitro cultured CSMSCs expressed some putative LESC markers, however, their overall 
expression pattern was more similar to their bone marrow-derived counterpart, rather than the in vitro cultured 
LESCs. It also implicates that our CSMSCs are different and not related to the LESC niche, respectively. Based 
upon the literature and our data obtained, the finding that ABCG2 is not a true LESC-specific marker is hereby 
strengthened, as this gene is widely expressed by many other tissue-specific stem- and/or progenitor cells as 
well21. ABCG2 plays a key role in the fetal protection functioning as a xenobiotics transporter, as well as serves a 
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Figure 5. The effect of inflammatory stimuli on the CSMSC expression of cell adhesion molecules and 
wound healing ability. The percentage of positive cells for CD54/ICAM-1 increased upon pro-inflammatory 
stimuli within the in vitro CSMSC cell cultures (A). Median fluorescent intensity (MFI) changed just in the case 
of CD47 molecules (B). Dot plot of the selected surface markers is being shown (C). Impedance-based wound 
healing assay results investigating the wound healing properties of CSMSCs under normal and inflammatory 
conditions. Cells were treated after wound creation by pro-inflammatory cytokines and TLR ligands, which 
prolonged the time of wound closure as shown by the Whiskers boxes (D). (N = 6 donors in triplicates, 
*p < 0.05 **p < 0.01 ***p < 0.001).
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protective function in the blood–brain barrier and the membranes of the hematopoietic and tissue resident stem 
cells22,23. This transporter is implicated as a Hoechst 33342 efflux pump, therefore, it is used to mark/or isolate 
the side population (SP-Hoechst negative) cells21,24. In corneal sections, ABCG2 labels SP cells in the limbus 
also (there being considered a putative marker)11. The detailed regulation of the expression of ABCG2, however, 
remains unclear as it is intensely controlled by the niche and the microenviroment of the cells22. In our dataset, 
it could implicate the size of the SP in the in vitro cell cultures. The amount of ABCG2+ cells in in vitro LESC 
cultures has been indeed controversial; there is a big variance between the used methods25–27; 2–4% of the LESCs 
cultured on mice feeder cells were found positive28, while the same amount could be reached with keratocyte 
medium cultivation as well25 (similar to our cultured CSMSCs), and in other model, the cell suspension and 
explant showed 50–85% positivity27. Interestingly, another ATP-binding cassette transporter (ABCB5) has been 
suggested to be an in situ specific LESC marker29,30, however, in our dataset, neither the in vitro cultured LESCs 
nor the CSMSCs expressed ABCB5. Interestingly, a weak expression could be detected only in one of the BMMSC 
donors (see Supplementary Fig. S1). As the expression of ABC transporters is mostly regulated by environmen-
tal factors, it is possible that the involved inducers are missing in the in vitro LESC/CSMSC/BMMSC cultures, 
respectively, as indicated by our data.
Further differences were observed in the surface molecular pattern between CSMSCs and LESCs. In compar-
ison to previous publications from our department19,31, the expression of CD44, CD90, CD105, CD117, CD140 
was higher-, and that of CD49f, CD104, CD146 and CXCR4 was less- in the MSC-like cells obtained from the 
central part of the cornea and compared to the LESCs. These differences indicate existence of different cell types 
within different microenvironments. In mice, MSC-like cells isolated from the central part of the corneal stroma 
exhibited similar phenotype except for a higher CD34 and CD45 positivity, with the canonical differentiation 
potential being shown there as well32,33. Due to the limited MSC markers studied in mice, a full comparison 
and correspondence to our results are not feasible33. These findings, however, strengthen the previous hypoth-
esis, that stem cells exist not just in the limbal epithelial crypts, but independently, in the central part of the 
cornea as well33–40. The morphology of the in vitro cultured CSMSCs were fibroblastoid, not stellate or den-
dritic, which is characteristic of keratocytes32,41. Furthermore, keratocytes are known to be positive for CD34 and 
CD133markers, which were not expressed by the CSMSCs42,43. In fact, different culture conditions such as the 
type of the basal medium, the glucose concentration and the percentage or type of serum being used can cause 
changes in the phenotype and possibly an epithelial – mesenchymal transition25,44,45. However, change in the 
phenotype would not only affect the CD34 molecule, but CD105 and CD90 as well44, which has been connected 
to a possible epithelial-mesenchymal transition25,46. In our culturing system, the CSMSCs retained the CD90 and 
CD105 marker, while lacking CD34 expression over more than 10 passages. We would hereby like to highlight 
that the ISCT defined criteria for MSCs require absence of CD34 and presence of CD105, not accepting the 
CD34+ population as MSCs20,47–50.
The immunosuppressive properties of MSCs have acquired much interest in the last few years. As previ-
ous reports indicate, MSCs are able to stimulate or suppress immune responses in vitro and in vivo by multi-
ple mechanisms51–55. Numerous studies have demonstrated that human MSCs avoid allorecognition, interfere 
with dendritic cells (DC) and T-cell functions, and generate a local immunosuppressive microenvironment51. 
MSCs are capable of inhibiting mitogen-stimulated lymphocyte proliferation in vitro51,56,57, and it is especially 
remarkable that our CSMSCs cultured in vitro possess similar immunosuppressive features, which phenomenon 
makes them potent candidates to treat ocular diseases with cell therapy. Such immunomodulatory effects could 
be observed and presumed in vivo40,58. While the immunosuppressive mechanisms of MSCs remain not fully 
clarified, the involvement of soluble factors, such as IL-6, IL-10, transforming growth factor β (TGFβ ), IFNγ, 
Galectin-1, Leukemia inhibitory factor (LIF) and Prostaglandin E2 (PGE2) have strongly been suggested as 
mediators of anti-immunosuppressive response59–62. IL-6 is needed for PGE2 production and secretion, whereas 
PGE2 plays a key role in the inhibition of T-cell proliferation and DC maturation55,59,63–66. It is now accepted that 
modulation of DC maturation by MSCs requires IL-6 and a contact-dependent mechanism63,67. However, IL-6 
can also act as a pro-angiogenic and migratory factor. Secreted by breast cancer cells in response to hypoxia, it 
increases the migratory effect of BMMSCs68. In clinical studies, elevated IL-6 concentrations could be measured 
within the aqueous humor from patients with endothelial rejection of corneal grafts, however, such findings 
could not be correlated with the rejection itself69–71. In rat corneal epithelial cells, the expression of HLA-DR 
and CD54/ICAM-1 increased upon TNFα and IFNγ treatments72, compared to our in vitro cultured CSMSCs 
in which changes in CD54 expression could only be detected, but none in HLA-DR. In human corneal epithelial 
cells, expression of MHC I-II proteins has been reported upon pro-inflammatory stimuli, which phenomenon 
could not be observed in our in vitro cultured CSMSCs. Keratocytes are sensitive to IL-1 and TNFα , which 
cytokines make them non-functional and apopototic - this phenomenon could not be observed in CSMSCs 
either41. Furthermore, keratocytes have not been described as immunosuppressive cells either, to the best of our 
knowledge73,74 - this function is only relevant to MSCs50,75,76. The outcome of the activation of MSCs by TLR 
ligands is controversial: activation by TLR3 and TLR4 ligands does not change their immune properties, but 
it inhibits their migratory effect as well as stimulates their adipogenic and osteogenic activity in case of TLR3 
ligands; the opposite effect is observed in case of TLR4 ligands77. In another study, Poly:IC increased the cycloox-
ygenase 2 (COX-2) expression in umbilical cord-derived MSCs and enhanced the immunosuppressive effects on 
the macrophages, respectively78,79. In human corneal myofibroblasts, but not keratocytes, Poly:IC could provoke 
IL-6 and IL-8 secretion80. In contrast, the activation of TLR3 and TLR4 of BMMSCs leads to elevated inhibitory 
effect on T-cell proliferation, respectively81; furthermore, it enhances immunosuppression in another manner18.
CXCL10 has recently been found to be one of the most important cytokines expressed by human limbal epi-
thelial progenitor cells at gene and protein level82–85. CXCL10 can act as a chemokine for MSCs83,86,87, and it has 
strong anti-angiogenic properties as well88–90. Our data suggest that this cytokine is probably specific for stem 
cells localized in the eye, while BMMSCs do not secrete it under normal conditions. CXCL10 secretion could 
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be provoked by TLR-3, TLR-4 ligands and IFNγ in bone marrow- and eye-derived MSCs, which was found to 
be similar to other MSCs isolated from various tissues, respectively81,91,92. In corneal fibroblasts, LPS treatment 
elevated the CD54/ICAM-1 expression and IL-8 secretion, behaving similar to our CSMSCs93. The mechanism of 
corneal wound healing has not been clarified yet, however, it is clear that the process is controlled under various 
cytokines and growth factors94. In stromal cells from keratoconic corneas, the level of TNFα was found increased, 
which is supposed to lead to defects in wound healing95, inhibiting CEC migration and proliferation96. Similar 
results were obtained in a herpetic stromal keratitis animal model, where increased TNFα and IL-1β was corre-
lated to the increased opacity of the tissue97. Alternatively, TNFα -treated MSCs were found to promote CEC sur-
vival, and inhibit apoptosis of these cells98. The lack of TNFα could elevate neovascularization and inflammation 
in an alkali-burn mouse cornea model46,99. Our in vitro cultured CSMSCs responded by elevated IL-6 secretion 
to TNFα exposure, which interleukin could be shown to promote corneal epithelial wound healing in a rabbit 
model100. IL-6 is strongly induced in alkali burns94,101, and supposed to be involved in the anti-inflammatory and 
anti-angiogenic action of MSCs in animal models of chemically burned corneas102,103 and during in vitro corneal 
wound healing modelling104. IL-1 can cause apoptosis of corneal myofibroblast, affecting physiological corneal 
wound healing105. Overall, the pro-inflammatory microenvironment can inhibit stromal cell function in the cor-
nea, resulting in abnormal cell survival and wound healing, which eventually lead to rejection of allografts106,107.
Bacterial infections of the cornea can cause reduced vision, tearing, pain, and when left untreated, can cause 
blindness. The bacterial wall compound LPS is known to inhibit CEC migration and wound healing108, and to 
stimulate neovascularization and inflammation in the cornea93,109. The TLR4 and TLR9 affected signaling path-
ways are MyD88-dependentin animal models110, which complex system can also include the NFκ B activation. 
Beside bacterial infection, viruses are able to provoke local immune and inflammatory responses in the cornea. 
Poly:IC increases the expression of vascular cell adhesion molecule (VCAM) and intercellular adhesion molecule 
-1 (ICAM-1) in human corneal fibroblasts111,112, while elevated secretion of IL-6, IL-8, IP-10 levels111,113 have been 
found to mediated by the NFκ B pathway111–113, and similar to our results. This pathway was responsible for trig-
gered IL-8 secretion in human corneas after adenoviral infection114. CECs also release IL-6 and IL-8 upon NFκ B 
modulation, again similar to how our CSMSCs behaved115. In sepsis, Poly:IC can improve the immunosuppres-
sive function of MSCs via the TLR3 pathway79.
It is well known, that MSCs are not immunosuppressive in common, but need to be primed to achieve the 
unique immunosuppressive behaviour62. The physical, chemical or biological damage of the tissue is usually 
accompanied by a “priming” local inflammation116. The outcome of MSC-mediated wound healing and immu-
nomodulation depends on the direct and indirect interactions with immune cells116. Prolonged inflammation 
inhibits the tissue regeneration potential of MSCs and leads to insufficient immunoregulatory activity116,117.
In conclusion, the central part of the human corneal stroma contains MSC-like cells with differentiation 
potential and possible immunosuppressive properties, suggesting that they can play an important role not just in 
the regeneration during tissue injury, but also in controlling the immune status of the microenvironment37. These 
properties make the CSMSCs plausible candidates for tissue engineering and future cell therapies for treating 
sight-threatening corneal diseases118.
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